Phase IIBreast cancer; Colorectal cancer; Solid tumours Phase I/IIBiliary cancer; Gastrointestinal cancer; HER2 positive breast cancer Most Recent Events 30 Oct 2024Phase-I/II clinical trials in Biliary cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresect...
Patritumab deruxtecan is currently being evaluated in a comprehensive development program across multiple cancers as both a monotherapy and in combination with other anticancer treatments. The development program includes aphase 2 studyin patients with ...
P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancerdoi:10.1016/j.annonc.2021.05.100K. RaghavT. YoshinoH. TaniguchiS. TejparA. VogelZ. WainbergK. Yamaguchi
The multi-center, open-label, two-cohort, two-part, phase 2 study will evaluate the safety and efficacy of patritumab deruxtecan in patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least two prior approved systemic therapies. Prior treatmen...
Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd’s response in women with early-stag